Sickle cell disease is an autosomal recessive disorder and the most common genetic disease affecting African-Americans. Mortality rates of sickle cell patients with pulmonary hypertension are hypothesized to be significantly increased as compared to patients without pulmonary hypertension. We have enrolled 270 patients in a study of the prevalence and prognosis of patients with sickle cell disease and pulmonary hypertension. All patients were screened with transthoracic echocardiograms and the tricuspid regurgitant jet velocity (TRV) used to estimate the pulmonary artery systolic pressure. Pulmonary hypertension was prospectively defined by a TRV >= 2.5 m/sec and severe pulmonary hypertension defined by a TRV >= 3.0 m/sec. Right heart catheterization was performed in consenting patients with TRV >= 2.8 m/sec. Based on these data, 32% of patients with sickle cell disease have elevated pulmonary artery systolic pressures (TRV >= 2.5 m/sec) and 9% have severely elevated pressures. Multiple-regression analysis identified increasing age, increased serum markers of hemolysis (LDH, total bilirubin) and arginine/ornithine ratio as significant independent predictors of pulmonary hypertension. Fetal hemoglobin levels did not predict pulmonary hypertension nor did hydroxyurea therapy modify pulmonary pressures. Left ventricular dysfunction was rarely observed (<2% of patients) and calculated pulmonary artery systolic pressures based on TRV accurately predicted measured values during right heart catheterization (r=0.98; p=0.001). The patients diagnosed with pulmonary hypertension had significantly greater mortality. These studies suggest that secondary pulmonary hypertension is common in adult patients with sickle cell disease, appears to be resistant to hydroxyurea therapy, is linked to hemolysis and is associated with a high mortality. These data suggest that all patients should be screened for this complication and considered for therapeutic trials with oxygen, anticoagulation, transfusion and/or selective pulmonary vasodilators. Patients continue to be enrolled in this trial and referred for treatment studies if identified with pulmonary hypertension. We have also enrolled 47 African American controls to determine the normal range of tricuspid regurgitant jet velocity who serve as a comparison for the sickle cell population being studied.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL001174-05
Application #
7213898
Study Section
(CCMD)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Taylor 6th, James G; Nolan, Vikki G; Mendelsohn, Laurel et al. (2008) Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 3:e2095
Taylor 6th, James G; Woods, Gerald M; Machado, Roberto et al. (2008) Severe pulmonary hypertension in an adolescent with sickle cell disease. Am J Hematol 83:71-2
Taylor 6th, James G; Ackah, Diana; Cobb, Crystal et al. (2008) Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol 83:6-14
Gordeuk, Victor R; Sachdev, Vandana; Taylor, James G et al. (2008) Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol 83:15-8
Sachdev, Vandana; Machado, Roberto F; Shizukuda, Yukitaka et al. (2007) Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol 49:472-9
Kato, Gregory J; Onyekwere, Onyinye C; Gladwin, Mark T (2007) Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol 24:159-70
Villagra, Jose; Shiva, Sruti; Hunter, Lori A et al. (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110:2166-72
Kato, Gregory J; Gladwin, Mark T; Steinberg, Martin H (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21:37-47
Kato, Gregory J; McGowan, Vicki; Machado, Roberto F et al. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107:2279-85
Machado, Roberto F; Anthi, Anastasia; Steinberg, Martin H et al. (2006) N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 296:310-8

Showing the most recent 10 out of 20 publications